^
    Back
    Association details:
    Biomarker:EGFR-GRB2 fusion
    Cancer:Lung Adenocarcinoma
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Cureus
    Title:

    The Treatment of a Novel Epidermal Growth Factor Receptor (EGFR)-GRB2 Genetic Mutation Using Osimertinib in Metastatic Non-Small Cell Lung Cancer

    Published date:
    04/24/2023
    Excerpt:
    We report on a unique EGFR-GRB2 fusion in a 48-year-old female never-smoker. This patient presented with stage IV lung adenocarcinoma…After treatment with osimertinib, this patient experienced remarkable clinical and radiological improvements.
    DOI:
    10.7759/cureus.38059